Bifogade filer
20260109_PM_Isofol_ASCO GI
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
GOTHENBURG, Sweden, January 9, 2026 - Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) announces today that the company will participate in the ASCO GI (American Society of Clinical Oncology Gastrointestinal Cancer) Symposium in San Francisco, US, January 8–10. An abstract describing the study design for Isofol’s ongoing phase Ib/II clinical study with arfolitixorin has been accepted for presentation at the congress.
The information in the press release is intended for investors.
Isofol is developing arfolitixorin – a proprietary clinical-stage drug candidate designed to enhance the efficacy of established cancer treatments. Based on extensive clinical research, arfolitixorin is now being tested in a phase Ib/II clinical study with an optimized dose regimen, conducted at the German hospital Charité – Universitätsmedizin Berlin. The drug candidate has the potential to fill a known treatment gap in cancer care.
At the annual ASCO GI Cancer Symposium, an abstract describing the study design of Isofol’s ongoing clinical phase Ib/II study will be presented. The abstract is a so-called TiP (Trial in Progress) abstract, covering the study design and recruitment status. The study evaluates a new dosing regimen and escalating doses of arfolitixorin in combination with 5-FU chemotherapy, as well as oxaliplatin and bevacizumab as first-line treatment in patients with metastatic colorectal cancer (mCRC).
The abstract is available on ASCO’s website >>
“We are thrilled that ASCO GI shows interest in our clinical development program with a drug candidate that has the potential to improve the efficacy of today’s and tomorrow’s standard of care treatment for cancer patients. It’s also a great start to the new year, where we aim to conclude the first part of the study and also initiate the following phase II part,” says Roger Tell, Chief Medical Officer at Isofol.
In connection with the participation at ASCO GI, Isofol will hold meetings with members of the company’s Advisory Board.
Colorectal cancer is the third most common form of cancer globally, and the second most common cause of cancer-related death, according to the World Health Organization (WHO). The need for new treatments in the field is, therefore, highly significant.
For more information, please contact
Isofol Medical AB (publ)
Petter Segelman Lindqvist, Chief Executive Officer
E-mail: petter.s.lindqvist@isofolmedical.com
Phone: +46 (0) 739 60 12 56
The information was submitted for publication, through the agency of the contact person set out above, at 07:30 CET on January 9, 2026.
About Isofol
Isofol Medical AB (publ) works to improve the quality of life and prognosis for patients with severe forms of cancer. The company's drug candidate arfolitixorin aims to increase the effect of first-line standard treatment for several forms of solid tumors and is currently being studied in colorectal cancer, the world's third most common cancer, where the medical need for better treatments is truly urgent. A phase Ib/II study is now being conducted with a new dosage regimen that is expected to optimize the effect of the drug candidate. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.